Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / why is lung disease focused theravance biopharma sto mwn benzinga


VTRS - Why Is Lung Disease Focused Theravance Biopharma Stock Trading Lower Today? | Benzinga

Theravance Biopharma Inc (NASDAQ: TBPH) announced results from the Phase 4 PIFR-2 study of Yupelri (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for maintenance treatment of chronic obstructive pulmonary disorder (COPD).

The PIFR-2 study aimed to demonstrate greater improvement in lung function for Yupelri delivered via standard jet nebulizer compared to Spiriva (tiotropium) delivered via a dry powder inhaler (Spiriva HandiHaler) in adults with severe to very severe COPD and suboptimal peak inspiratory flow rate (PIFR).

The study did not ...

Full story available on Benzinga.com

Stock Information

Company Name: Viatris Inc.
Stock Symbol: VTRS
Market: NASDAQ

Menu

VTRS VTRS Quote VTRS Short VTRS News VTRS Articles VTRS Message Board
Get VTRS Alerts

News, Short Squeeze, Breakout and More Instantly...